Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

Data ReadoutDabogratinibNegative

AI Analysis

Summary

Article raises concerns about Tyra Biosciences' reliance on dabogratinib with renewed skepticism surrounding the SURF-302 trial. Limited explicit details provided in the headline-only excerpt.

Clinical Trial Data

NCT ID

SURF-302

Importance:4/10

Sentiment:

-0.50

clinical_trialdrug_developmentskepticismpipeline_risk

Related Companies

$TYRA

Read the original article

Published by yahoo_finance on June 12, 2026 1:16 AM

Read Original